Synthesis of 1,3,4-thiadiazole derivatives as aminopeptidase N inhibitors

Pharmazie

Volumn 64, Issue 2, 2009, Pages 67-70

  Li, Shao Hua ^a   Li, Gang ^a   Huang, Hui Ming ^a   Xiong, Fang ^a   Mai, Xi ^a   Kuang, Bin Hai ^a   Liu, Cheng Mei ^a   Tu, Guo Gang ^a  

^a NANCHANG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BESTATIN; MICROSOMAL AMINOPEPTIDASE; N(5 PHENYL 1,3,4 THIADIAZOL 2 YL) 2 [(BENZOYL)AMINO]PROPANAMIDE; N(5 PHENYL 1,3,4 THIADIAZOL 2 YL) 2 [(PHENYLACETYL)AMINO]PROPANAMIDE; N(5 PHENYL 1,3,4 THIADIAZOL 2 YL) 2 [(PHENYLSULFONYL)AMINO]PROPANAMIDE; N[5 (4 BROMOPHENYL) 1,3,4 THIADIAZOL 2 YL] 2 [(BENZOYL)AMINO]PROPANAMIDE; N[5 (4 BROMOPHENYL) 1,3,4 THIADIAZOL 2 YL] 2 [(PHENYLACETYL)AMINO]PROPANAMIDE; N[5 (4 BROMOPHENYL) 1,3,4 THIADIAZOL 2 YL] 2 [(PHENYLSULFONYL)AMINO]PROPANAMIDE; N[5 (4 CHLOROPHENYL) 1,3,4 THIADIAZOL 2 YL] 2 [(BENZOYL)AMINO]PROPANAMIDE; N[5 (4 CHLOROPHENYL) 1,3,4 THIADIAZOL 2 YL] 2 [(PHENYLACETYL)AMINO]PROPANAMIDE; N[5 (4 CHLOROPHENYL) 1,3,4 THIADIAZOL 2 YL] 2 [(PHENYLSULFONYL)AMINO]PROPANAMIDE; N[5 (4 FLUOROPHENYL) 1,3,4 THIADIAZOL 2 YL] 2 [(BENZOYL)AMINO]PROPANAMIDE; N[5 (4 FLUOROPHENYL) 1,3,4 THIADIAZOL 2 YL] 2 [(PHENYLACETYL)AMINO]PROPANAMIDE; N[5 (4 FLUOROPHENYL) 1,3,4 THIADIAZOL 2 YL] 2 [(PHENYLSULFONYL)AMINO]PROPANAMIDE; N[5 (4 METHOXYLPHENYL) 1,3,4 THIADIAZOL 2 YL] 2 [(BENZOYL)AMINO]PROPANAMIDE; N[5 (4 METHOXYPHENYL) 1,3,4 THIADIAZOL 2 YL] 2 [(PHENYLACETYL)AMINO]PROPANAMIDE; N[5 (4 METHOXYPHENYL) 1,3,4 THIADIAZOL 2 YL] 2 [(PHENYLSULFONYL)AMINO]PROPANAMIDE; N[5 (4 METHYLPHENYL) 1,3,4 THIADIAZOL 2 YL] 2 [(BENZOYL)AMINO]PROPANAMIDE; N[5 (4 METHYLPHENYL) 1,3,4 THIADIAZOL 2 YL] 2 [(PHENYLACETYL)AMINO]PROPANAMIDE; N[5 (4 METHYLPHENYL) 1,3,4 THIADIAZOL 2 YL] 2 [(PHENYLSULFONYL)AMINO]PROPANAMIDE; N[5 (4 NITROPHENYL) 1,3,4 THIADIAZOL 2 YL] 2 [(BENZOYL)AMINO]PROPANAMIDE; N[5 (4 NITROPHENYL) 1,3,4 THIADIAZOL 2 YL] 2 [(PHENYLACETYL)AMINO]PROPANAMIDE; N[5 (4 NITROPHENYL) 1,3,4 THIADIAZOL 2 YL] 2 [(PHENYLSULFONYL)AMINO]PROPANAMIDE; PEPTIDE HYDROLASE INHIBITOR; THIADIAZOLE DERIVATIVE; UNCLASSIFIED DRUG; DRUG DERIVATIVE; DYES, REAGENTS, INDICATORS, MARKERS AND BUFFERS; GELATINASE A; LEUCINE; PROTEINASE INHIBITOR;

ARTICLE; CANCER CHEMOTHERAPY; DRUG DESIGN; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; IC 50; IN VITRO STUDY; NONHUMAN; CHEMISTRY; DRUG ANTAGONISM; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

ANTIGENS, CD13; INDICATORS AND REAGENTS; LEUCINE; MATRIX METALLOPROTEINASE 2; PROTEASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP; THIADIAZOLES;

EID: 65349096735     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: 10.1691/ph.2009.8630     Document Type: Article

References (31)

1. Abe T, Yamamoto Y, Hazato T (1998) Changes in aminopeptidase N located on neutrophils derived from patients with chronic pain. Masui 47: 151-155.
2. Andersson L, Isley TC, Wolfenden R (1982) alpha-aminoaldehydes: transition state analogue inhibitors of leucine aminopeptidase. Biochemistry 21: 4177-4180.
3. Antczak C, De Meester I, Bauvois B (2001) Ectopeptidases in pathophysiology. Bioassays 23: 251-260.
4. Balog T, Marotti T, Sverko V, Marott M, Krolo I, Rocic B, Karapanda, N (2003) Enkephalin degradating enzymes in pheochromocytoma patients. Oncol Rep10: 253-258.
5. Baragi VM, Shaw BJ, Renkiewicz RR, Kuipers PJ, Welgus HG, Mathrubutham M, Cohen JR, Rao SK (2000) A versatile assay for gelatinases using succinylated gelatin. Matrix Biol 19: 267-273.
6. Bauvois B, Dauzonne D (2006) Aminopeptidase-N/CD13 (EC 3.4.11.2) inhibitors: chemistry, biological evaluations, and therapeutic prospects. Med Res Rev 26: 88-130.
7. Becker JW, Marcy AI, Rokosz LL, Axel MG, Burbaum JJ, Fitzgerald PM, Cameron PM, Esser CK, Hagmann WK, Hermes JD, Springer JP (1995) Stromelysin-1: three-dimensional structure of the inhibited catalytic domain and of the C-truncated proenzyme. Protein Sci 4: 1966-1976.
8. Boldt DH, Kopecky KJ, Head D, Gehly G, Radich JP, Appelbaum FR (1994) Expression of myeloid antigens by blast cells in acute lympho-blastic leukemia of adults. The Southwest Oncology Group experience. Leukemia 8: 2118-2126.
9. Carl-McGrath S, Lendeckel U, Ebert M, Wolter AB, Roessner A, Rocken C (2004) The ectopeptidases CD10, CD13, CD26, and CD143 are upregulated in gastric cancer. Int J Oncol 25: 1223-1232.
10. Dan H, Tani K, Hase K, Shimizu T, Tamiya H, Biraa Y, Huang L, Yanagawa H, Sone S (2003) CD13/aminopeptidase N in collagen vascular diseases. Rheumatol Int 23: 271-276.
11. + anaplastic large-cell lymphoma with aberrant expression of CD13: Case report and review of the literature. J Clin Lab Anal 14: 299-304.
12. Fournié-Zaluski MC, Coric P, Turcaud S, Bruetschy L, Lucas E, Noble F, Roques BP (1992) Potent and systemically active aminopeptidase N inhibitors designed from active-site investigation. J Med Chem 35: 1259-1266.
13. Fujii H, Nakajima M, Saiki I, Yoneda J, Azuma I, Tsuruo T (1995) Human melanoma invasion and metastasis enhancement by high expression of aminopeptidase N/CD13. Clin Exp Metastasis 13: 337-344.
14. Grujić M, Renko M (2002) Aminopeptidase inhibitors bestatin and actinonin inhibit cell proliferation of myeloma cells predominantly by intracellular interactions. Cancer Lett 182: 113-119.
15. Harding JW, Felix D (1987) The effects of the aminopeptidase inhibitors amastatin and bestatin on angiotensin-evoked neuronal activity in rat brain. Brain Res 424: 299-304.
16. Hashida H, Takabayashi A, Kanai M, Adachi M, Kondo K, Kohno N, Yamaoka Y, Miyake M (2002) Aminopeptidase N is involved in cell motility and angiogenesis: Its clinical significance in human colon cancer. Gastroenterology 122: 376-386.
17. Ikeda N, Nakajima Y, Tokuhara T, Hattori N, Sho M, Kanehiro H, Miyake M (2003) Clinical significance of aminopeptidase N/CD13 expression in human pancreatic carcinoma. Clin Cancer Res 9: 1503-1508.
18. Ishii K, Usui S, Sugimura Y, Yamamoto H, Yoshikawa K, Hirano K (2001) Inhibition of aminopeptidase N(AP-N) and urokinase-type plasminogen activator (uPA) by zinc suppresses the invasion activity in human urological cancer cells. Biol Pharm Bull 24: 226-230.
19. Kehlen A, Lendeckel U, Dralle H, Langner J, Hoang-Vu C (2003) Biological significance of aminopeptidase N/CD13 in thyroid carcinomas. Cancer Res 63: 8500-8506.
20. Lejczak B, Kafarski P, Zygmunt J (1989) Inhibition of aminopeptidases by aminophosphonates. Biochemistry 28: 3549-3555.
21. Levy M, Palmer AH (1942) The benzoylation and resolution alanine. J Biol Chem 146: 493-495.
22. Lohn M, Mueller C, Langner J (2002) Cell cycle retardation in monocytoid cells induced by aminopeptidase N (CD13). Leuk Lymphoma 43: 407-413.
23. Menrad A, Speicher D, Wacker J, Herlyn M (1993) Biochemical and functional characterization of aminopeptidase N expressed by human melanoma cells. Cancer Res 53: 1450-1455.
24. Popnikolov NK, Payne DA, Hudnall SD, Hawkins HK, Kumar M, Norris BA, Elghetany MT (2000) CD13-positive anaplastic large cell lymphoma of T-cell origin - a diagnostic and histogenetic problem. Arch Pathol Lab Med 124: 1804-1808.
25. Riemann D, Kehlen A, Langner J (1999a) CD13 - not just a marker in leukemia typing. Immunol Today 20: 83-88.
26. Riemann D, Gohring B, Langner, J (1994b) Expression of aminopeptidase N/CD13 in tumour-infiltrating lymphocytes from human renal cell carcinoma. Immunol Lett 42: 19-23.
27. Saiki I, Fujii H, Yoneda J, Abe F, Nakajima M, Tsuruo T, Azuma I (1993) Role of aminopeptidase N (CD13) in tumor-cell invasion and extracellular matrix degradation. Int J Cancer 54: 137-143.
28. Shenvi AB (1986) alpha-Aminoboronic acid derivatives: effective inhibitors of aminopeptidases. Biochemistry 25: 1286-1291.
29. Song KS, Ishikawa Y, Kobayashi S, Sankawa U, Ebizuka Y (1992) NAcylamino acids from Ephedra distachya cultures. Phytochemistry 31: 823-826.
30. Tatsumi E (2002) A mini-review of CD13 antigen in AML: Easy induction or enhancement of expression in in vitro culture and necessary consideration for assessment. Southeast Asian J Trop Med Public Health 33(Suppl 2): 155-157.
31. van Hensbergen Y, Broxterman HJ, Hanemaaijer R, Jorna AS, van Lent NA, Verheul HM, Pinedo HM, Hoekman K (2002) Soluble aminopeptidase N/CD13 in malignant and nonmalignant effusions and intratumoral fluid. Clin Cancer Res 8: 3747-3754.